NPCE icon

Neuropace

10.91 USD
-0.03
0.27%
At close Apr 23, 4:00 PM EDT
After hours
10.91
+0.00
0.00%
1 day
-0.27%
5 days
7.49%
1 month
-11.30%
3 months
-22.18%
6 months
84.92%
Year to date
-5.79%
1 year
-22.13%
5 years
-56.29%
10 years
-56.29%
 

About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Employees: 184

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

2,500% more call options, than puts

Call options by funds: $260K | Put options by funds: $10K

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

126% more capital invested

Capital invested by funds: $103M [Q3] → $234M (+$130M) [Q4]

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

29% more funds holding

Funds holding: 48 [Q3] → 62 (+14) [Q4]

19.24% more ownership

Funds ownership: 50.67% [Q3] → 69.91% (+19.24%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$17
56%
upside
Avg. target
$18.50
70%
upside
High target
$20
83%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Ross Osborn
20% 1-year accuracy
9 / 45 met price target
83%upside
$20
Overweight
Maintained
5 Mar 2025
Wells Fargo
Larry Biegelsen
22% 1-year accuracy
10 / 46 met price target
56%upside
$17
Overweight
Maintained
30 Jan 2025

Financial journalist opinion

Based on 5 articles about NPCE published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
NeuroPace Provides Update on Tariff Status
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 --
NeuroPace Provides Update on Tariff Status
Neutral
GlobeNewsWire
2 weeks ago
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1 Long-term seizure reduction with a median reduction of 82% at 3 years. Seizure freedom with 42% of patients remaining seizure free for 6+ months.i MOUNTAIN VIEW, Calif.
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
Neutral
GlobeNewsWire
2 weeks ago
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9.
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
Neutral
GlobeNewsWire
3 weeks ago
NeuroPace Announces Refocusing of Product Portfolio
-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that as part of a strategic refocusing of its product portfolio on its core, differentiated RNS System product line, it is terminating its distribution relationship for SEEG products and will begin winding down the relationship in the fourth quarter of 2025 and continuing through the first quarter of 2026.
NeuroPace Announces Refocusing of Product Portfolio
Neutral
GlobeNewsWire
4 weeks ago
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025.
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
Neutral
Seeking Alpha
1 month ago
NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolfe Research Operator Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million --
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference.
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
NeuroPace to Present at the Leerink Partners Global Healthcare Conference
MOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, January 10, 2025, in Miami, FL. Management will also host investor meetings during the conference.
NeuroPace to Present at the Leerink Partners Global Healthcare Conference
Positive
Zacks Investment Research
2 months ago
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?
Charts implemented using Lightweight Charts™